Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1950 1
1951 1
1981 1
1990 2
1991 1
1993 1
1994 1
1995 1
1996 1
2000 2
2003 3
2004 3
2005 3
2006 2
2007 2
2008 2
2009 2
2010 3
2011 11
2012 12
2013 8
2014 3
2015 6
2016 8
2017 9
2018 8
2019 21
2020 15
2021 24
2022 21
2023 35
2024 25
2025 36
2026 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Results by year

Filters applied: . Clear all
Page 1
Lecanemab: Appropriate Use Recommendations.
Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC, Salloway S. Cummings J, et al. Among authors: atri a. J Prev Alzheimers Dis. 2023;10(3):362-377. doi: 10.14283/jpad.2023.30. J Prev Alzheimers Dis. 2023. PMID: 37357276 Free PMC article.
Donanemab: Appropriate use recommendations.
Rabinovici GD, Selkoe DJ, Schindler SE, Aisen P, Apostolova LG, Atri A, Greenberg SM, Hendrix SB, Petersen RC, Weiner M, Salloway S, Cummings J. Rabinovici GD, et al. Among authors: atri a. J Prev Alzheimers Dis. 2025 May;12(5):100150. doi: 10.1016/j.tjpad.2025.100150. Epub 2025 Mar 27. J Prev Alzheimers Dis. 2025. PMID: 40155270 Free PMC article.
Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care.
Atri A, Dickerson BC, Clevenger C, Karlawish J, Knopman D, Lin PJ, Norman M, Onyike C, Sano M, Scanland S, Carrillo M. Atri A, et al. Alzheimers Dement. 2025 Jun;21(6):e14333. doi: 10.1002/alz.14333. Epub 2024 Dec 23. Alzheimers Dement. 2025. PMID: 39713942 Free PMC article.
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.
Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, Johannsen P, León T, Scheltens P. Cummings JL, et al. Among authors: atri a. Alzheimers Res Ther. 2025 Jan 8;17(1):14. doi: 10.1186/s13195-024-01666-7. Alzheimers Res Ther. 2025. PMID: 39780249 Free PMC article. Clinical Trial.
The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care.
Dickerson BC, Atri A, Clevenger C, Karlawish J, Knopman D, Lin PJ, Norman M, Onyike C, Sano M, Scanland S, Carrillo M. Dickerson BC, et al. Among authors: atri a. Alzheimers Dement. 2025 Jan;21(1):e14337. doi: 10.1002/alz.14337. Epub 2024 Dec 23. Alzheimers Dement. 2025. PMID: 39713957 Free PMC article.
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
Bateman RJ, Li Y, McDade EM, Llibre-Guerra JJ, Clifford DB, Atri A, Mills SL, Santacruz AM, Wang G, Supnet C, Benzinger TLS, Gordon BA, Ibanez L, Klein G, Baudler M, Doody RS, Delmar P, Kerchner GA, Bittner T, Wojtowicz J, Bonni A, Fontoura P, Hofmann C, Kulic L, Hassenstab J, Aschenbrenner AJ, Perrin RJ, Cruchaga C, Renton AE, Xiong C, Goate AA, Morris JC, Holtzman DM, Snider BJ, Mummery C, Brooks WS, Wallon D, Berman SB, Roberson E, Masters CL, Galasko DR, Jayadev S, Sanchez-Valle R, Pariente J, Kinsella J, van Dyck CH, Gauthier S, Hsiung GR, Masellis M, Dubois B, Honig LS, Jack CR, Daniels A, Aguillón D, Allegri R, Chhatwal J, Day G, Fox NC, Huey E, Ikeuchi T, Jucker M, Lee JH, Levey AI, Levin J, Lopera F, Roh J, Rosa-Neto P, Schofield PR; Dominantly Inherited Alzheimer's Disease–Trials Unit. Bateman RJ, et al. Among authors: atri a. Lancet Neurol. 2025 Apr;24(4):316-330. doi: 10.1016/S1474-4422(25)00024-9. Lancet Neurol. 2025. PMID: 40120616 Free PMC article. Clinical Trial.
A US-based practitioner's guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer's dementia - recommendations of an expert, multispecialty advisory panel.
Grossberg GT, Sanford A, Montano CB, Porsteinsson AP, Scanland S, Worz C, McMillian S, Atri A. Grossberg GT, et al. Among authors: atri a. Postgrad Med. 2025 Aug;137(6):469-485. doi: 10.1080/00325481.2025.2517535. Epub 2025 Jun 17. Postgrad Med. 2025. PMID: 40497644 Free article. Review.
Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis.
Liss JL, Seleri Assunção S, Cummings J, Atri A, Geldmacher DS, Candela SF, Devanand DP, Fillit HM, Susman J, Mintzer J, Bittner T, Brunton SA, Kerwin DR, Jackson WC, Small GW, Grossberg GT, Clevenger CK, Cotter V, Stefanacci R, Wise-Brown A, Sabbagh MN. Liss JL, et al. Among authors: atri a. J Intern Med. 2021 Aug;290(2):310-334. doi: 10.1111/joim.13244. Epub 2021 Mar 31. J Intern Med. 2021. PMID: 33458891 Free PMC article. Review.
264 results